login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
DYNE THERAPEUTICS INC (DYN) Stock News
USA
-
Nasdaq
- NASDAQ:DYN -
US26818M1080
-
Common Stock
19.55
USD
-0.04 (-0.2%)
Last: 12/16/2025, 8:16:53 PM
19.87
USD
+0.32 (+1.64%)
After Hours:
12/16/2025, 8:16:53 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
DYN Latest News, Press Relases and Analysis
All
Press Releases
5 days ago - By: Dyne Therapeutics, Inc.
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
5 days ago - By: Dyne Therapeutics, Inc.
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
6 days ago - By: The Motley Fool
- Mentions:
OPY
Why Dyne Therapeutics Stock Was a Big Winner on Wednesday
7 days ago - By: Dyne Therapeutics, Inc.
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock
2 months ago - By: Stocktwits
- Mentions:
RNA
NVS
Dyne Therapeutics Stock Soars After Rival Avidity Biosciences Gets Acquired By Novartis
7 days ago - By: Dyne Therapeutics, Inc.
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock
7 days ago - By: The Motley Fool
- Mentions:
MS
JEF
Why Dyne Therapeutics Stock Tanked on Tuesday
8 days ago - By: Dyne Therapeutics, Inc.
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
8 days ago - By: Dyne Therapeutics, Inc.
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
9 days ago - By: Dyne Therapeutics, Inc.
Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
9 days ago - By: Dyne Therapeutics, Inc.
Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
9 days ago - By: Dyne Therapeutics, Inc.
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET
9 days ago - By: Dyne Therapeutics, Inc.
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET
a month ago - By: Benzinga
- Mentions:
TERN
SGML
COCO
IVVD
...
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday
a month ago - By: Dyne Therapeutics, Inc.
Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
a month ago - By: Dyne Therapeutics, Inc.
Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
a month ago - By: Dyne Therapeutics, Inc.
Dyne Therapeutics to Present at Upcoming Investor Conferences
a month ago - By: Dyne Therapeutics, Inc.
Dyne Therapeutics to Present at Upcoming Investor Conferences
2 months ago - By: Benzinga
- Mentions:
PRE
GNTA
RNA
SMLR
...
12 Health Care Stocks Moving In Monday's Intraday Session
2 months ago - By: Dyne Therapeutics, Inc.
Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
2 months ago - By: Dyne Therapeutics, Inc.
Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
3 months ago - By: Dyne Therapeutics, Inc.
Dyne Therapeutics Appoints Brian Posner to its Board of Directors
3 months ago - By: Dyne Therapeutics, Inc.
Dyne Therapeutics Appoints Brian Posner to its Board of Directors
3 months ago - By: Dyne Therapeutics, Inc.
Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy
3 months ago - By: Dyne Therapeutics, Inc.
Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy
4 months ago - By: Dyne Therapeutics, Inc.
Dyne Therapeutics to Present at Upcoming Investor Conferences
Please enable JavaScript to continue using this application.